Skip to main content
GoodMoatv1.1
Sign in
BIIB logo

BIIB

CompareEarnings: May 31, 2026

Biogen Inc

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority. About the Collaboration between Eisai and BioArctic for AD Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. About Eisai Co., Ltd. Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care ( hhc ) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

Did you know?

Earnings per share grew at a -17.5% CAGR.

Current Price

$177.34

-3.50%

GoodMoat Value

$108.82

38.6% overvalued
Profile
Valuation (TTM)
Market Cap$26.02B
P/E20.12
EV$29.70B
P/B1.43
Shares Out146.70M
P/Sales2.63
Revenue$9.89B
EV/EBITDA12.28

Biogen Inc (BIIB) Financial Statements

GoodMoat Analysis

Based on data as of March 26, 2026

Biogen's financial quality is currently unfavourable for a value investor, primarily due to declining revenue and weak profitability metrics. While free cash flow generation is adequate and the balance sheet is healthy, the core business shows signs of deterioration.

Read full analysis
Biogen's financial health presents a mixed picture with concerning trends in its core operations. Revenue declined -7.1% year-over-year, which is a significant negative indicator for growth and business momentum. The company's profitability metrics are weak relative to the framework's high-quality thresholds; an ROE of 7.1% is well below the 15-20% target for a durable moat, and an operating margin of 15.7% suggests limited operating leverage. The 13.1% profit margin is also modest for a pharmaceutical company. On a more favourable note, the free cash flow yield of 7.3% indicates the business is still generating solid cash, which is a key quality indicator. The balance sheet appears healthy with a manageable debt-to-equity ratio of 0.36, which is below the cautionary level of 1.0x Debt/EBITDA implied by the framework, providing financial flexibility. However, the overarching theme is one of a business in transition or decline, as negative revenue growth severely undermines the assessment of quality and growth trajectory, making it difficult to score highly on the framework's systematic criteria.

BIIB Financial Data

EBITDA$2.34B
Revenue (TTM)$9.89B
Gross Profit (TTM)$7.49B
Gross Margin—
Operating Margin15.74%
ROE7.08%
ROA4.39%
Debt/Equity0.36
Current Ratio2.68
FCF$2.02B
FCF Yield7.76%
Piotroski F-Score—
Rev/Share (TTM)$67.42
50-Day MA$186.02
200-Day MA$159.23
Shares Outstanding0.15B

BIIB Computed Insights

FCF$2.02B
FCF Growth Rate-17.51%
EPS Growth (CAGR)-17.51%
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

BIIB Financial Statements & Data

Biogen Inc (BIIB) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Biogen Inc's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $9.89B. Gross profit (TTM) is $7.49B. EBITDA is $2.34B. Earnings per share (EPS) is $8.79. The P/E ratio is 20.12. Market capitalization is $26.02B.

Free cash flow (FCF) is $2.02B. FCF growth rate is -17.51%. EPS growth CAGR is -17.51%. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use Biogen Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.